TCR2 Therapeutics wins U.S. Private Company of the Year Award at LifeStars Awards™ Life Sciences 2018 Event

Thursday, November 29, 2018 Lifestyle News
Email Print This Page Comment bookmark
Font : A-A+

Recognition for pioneering new approaches in T cell immunotherapy

CAMBRIDGE, Mass., Nov. 29, 2018 /PRNewswire/ -- TCR2 Therapeutics Inc., an innovative immunotherapy company

developing the next generation of novel T cell receptor therapies for patients suffering from cancer, is pleased to announce that it has received the U.S. Private Company of the Year award at the 2018 LifeStars Awards™ event in London.

"We are delighted that the people of TCR2 Therapeutics have been recognized by their peers through this highly coveted international award," said Garry Menzel, Ph.D., President and Chief Executive Officer. "It is a testimony to the passion and hard work of our world-class team and scientific collaborators as we seek to drive our lead programs into the clinic to make a positive difference in the lives of people with cancer."

The LifeStars event was a celebration of the success stories, innovations, transformational deals and the people, teams and organizations that play such a critical role in the advancement of the industry over the last 12 months across Europe and the U.S. 

The international awards brought together more than 300 global life science leaders, investors, deal makers and key stakeholders from all sectors of the biotechnology eco-system to recognize the achievements of the industry. Twenty awards were contested during a prestigious gala dinner hosted at the Honourable Artillery Company in London, UK during the Jefferies Annual Healthcare Conference. Proceeds supported UNICEF.

"LifeStars presented a fantastic opportunity to bring together a deserved audience and highlight the advances being made in our industry. It's a testament to the team at TCR2 Therapeutics that this year's judging faculty commended them in this manner," said Neil Darkes, Co-CEO, LSX Ltd. and LifeStars™.

About TCR2 TherapeuticsTCR2 is an innovative immunotherapy company developing the next generation of novel T cell therapies for patients suffering from cancer. Our proprietary TCR Fusion Construct T cells (TRuC-T cells) specifically recognize and kill cancer cells by harnessing the entire T cell receptor (TCR) signaling complex, which we believe is essential for T cell therapies to be effective in patients with solid tumors. We have also designed our TRuC-T cells so that tumor cell recognition does not require human leukocyte antigens (HLA), which provides two important additional benefits. First, in contrast to current engineered T cell therapies that use the full TCR (TCR-T cells), our technology is designed so that it can be applied to all patients that express the cancer surface antigen irrespective of HLA subtype, which we believe will allow us to address a significantly larger patient population. Second, HLA is downregulated or lost in many tumors which can prevent their recognition by T cells and lead to diminished response rates and higher relapse rates. We therefore believe our approach will allow us to deliver the first HLA-independent TCR-T cell therapy for patients with solid tumors. We also believe that our product candidates have the potential to improve upon the efficacy and safety of currently approved chimeric antigen receptor T (CAR-T) cell therapies in CD19-positive B-cell hematological malignancies. This belief is based on preclinical studies comparing our product candidates to CAR-T cells that we engineered. We plan to file an IND for our lead solid tumor program, TC-210, targeting mesothelin in early 2019. TCR2 was founded in 2015 by renowned German immunologist Dr. Patrick Baeuerle and now led by a world-class team of immunotherapy experts and entrepreneurs in the heart of Kendall Square in Cambridge, MA. For more information, please visit

About LifeStars™The LifeStars™ Awards are organized by LSX, an influential community of senior life science decision makers. Through impactful events, powerful thought leadership content and unique networking opportunities, LSX exists to forge a fundamentally better way to promote and facilitate investment, financing, partnerships and deal making in healthcare. For more information please visit  


Cision View original content:

SOURCE TCR2 Therapeutics

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z


News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store